Possible pharmacological target for inhibition of HIV integration

A tétel rövid nézete
dc.contributor.advisorPórszász, Róbert
dc.contributor.advisordeptDebreceni Egyetem::Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézet
dc.contributor.authorTokimitsu, Shigeki
dc.contributor.departmentDE--Általános Orvostudományi Kar
dc.contributor.opponentMegyeri, Attila
dc.contributor.opponentDrimba, László
dc.contributor.opponentdeptDebreceni Egyetem::Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézet
dc.contributor.opponentdeptDebreceni Egyetem::Általános Orvostudományi Kar::Aneszteziológiai és Intenzív Terápiás Tanszék
dc.date.accessioned2023-10-12T09:46:21Z
dc.date.available2023-10-12T09:46:21Z
dc.date.created2023-10-05
dc.description.abstractThe treatment of HIV/AIDS involves the use of multiple antiretroviral drugs categorized into six major classes that target different stages of the HIV life cycle. This comprehensive approach, known as antiretroviral therapy (ART), has significantly reduced morbidity and mortality associated with HIV/AIDS. ART regimens typically consist of a combination of two nucleoside drugs and one drug from a different class. ART not only helps maintain immune system function but also prevents opportunistic infections and reduces the overall burden of HIV infection. It also plays a crucial role in preventing HIV transmission between individuals, provided the patient maintains an undetectable viral load. The success of ART has transformed HIV into a chronic condition in many parts of the world, with the progression to AIDS becoming increasingly rare. The understanding of the HIV life cycle, consisting of six stages, has been pivotal in the development of effective antiretroviral therapies. These therapies include Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Integrase Strand Transfer Inhibitors (INSTIs), Protease Inhibitors (PIs), and other agents for multidrug-resistant HIV. New classes of drugs, such as attachment inhibitors, capsid inhibitors, and post-attachment inhibitors, are being developed to enhance treatment effectiveness and reduce side effects. Integrase Binding Inhibitors (INBIs) specifically target the HIV-1 integrase enzyme, playing a crucial role in preventing viral replication.
dc.description.courseáltalános orvos
dc.description.courselangangol
dc.description.degreeegységes, osztatlan
dc.format.extent43
dc.identifier.urihttps://hdl.handle.net/2437/359748
dc.language.isoen
dc.rights.accessHozzáférhető a 2022 decemberi felsőoktatási törvénymódosítás értelmében.
dc.subjectHIV
dc.subjectAIDS
dc.subjectART
dc.subject.dspaceDEENK Témalista::Orvostudomány::Farmakológia
dc.titlePossible pharmacological target for inhibition of HIV integration
Fájlok
Gyűjtemények
Theses (Faculty of Medicine)